Piramal Enterprises Announces Sale of Its Hyderabad Based Clinical Research Division to Indoco Remedies
Piramal Enterprises Limited (‘PEL’, NSE: PEL, BSE: 500302) today announced that it has signed a definitive agreement to sell its clinical research division known as ‘Piramal Clinical Research (PCR)’ (formerly known as Wellquest), to Indoco Remedies Limited (Indoco) on a going concern basis for cash. - May 09, 2015
Piramal Fund Management Expands Offering to Include Construction Finance; Approves Transactions Worth INR1100cr in the First Instance
Piramal Fund Management had announced its intention to enter the construction finance space in Q3 FY15. Today, it announces that has approved 9 construction finance proposals totalling INR1100cr. - March 21, 2015
Piramal Enterprises Announces Q2 & H1FY 2015 Results
Revenues for Q2FY2015 were higher by 10.1% at 1,245 Crores. Operating profit for Q2FY2015 was higher by 40.1% at 212 Crores. PAT was impacted by one time write down sand costs related to scaling back of NCE operations during the quarter amounting to 374 Crores. - October 30, 2014
Piramal Enterprises’ Pharma Solution Division Receives Two Coveted CMO Leadership Awards (2013) for "Quality" and "Reliability"
Piramal Enterprises’ Pharma Solutions Division, a global pharmaceutical contract development and manufacturing organization(CDMO), has received CMO Leadership Awards 2013 in two categories–Quality and Reliability, at a prestigious ceremony at DCAT in NewYork. Within the Reliability... - May 11, 2014
Piramal Enterprises Limited ("Piramal") Agrees to Acquire 20% Equity Stake in Shriram Capital Limited ("Shriram Capital")
Piramal Enterprises Ltd.(“Piramal”, NSE: PEL, BSE: 500302) today announced that it has agreed to acquire an effective 20% equity stake in Shriram Capital Limited (“Shriram Capital” or “Company”), a financial services company, for an aggregate consideration of Rs. - May 11, 2014
Piramal Enterprises Limited ("Piramal") Agrees to Sell Equity Stake in Vodafone India Limited
Piramal Enterprises Ltd. (“Piramal”, NSE: PEL, BSE: 500302) today announced that it has agreed to divest its entire equity stake, comprising 45,425,328 shares (~11%), in Vodafone India Limited to Prime Metals Ltd., an indirect subsidiary of Vodafone Group Plc, for a total consideration... - May 09, 2014
NeuraceqTM (Florbetaben F18 Injection) Data: an Emerging Science Topic at the American Academy of Neurology Annual Meeting in Philadelphia
Piramal Imaging today announced that data from its beta-amyloid PET tracer NeuraceqTM clinical trial will be featured as part of Emerging Science sessions at the 66th American Academy of Neurology Annual Meeting at the Pennsylvania Convention Center Philadelphia, Penn. A presentation by Marwan... - May 04, 2014